A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine(R)) in mild dementia

Ole J Thienhaus, B. G. Wheeler, S. Simon, F. P. Zemlan, J. T. Hartford

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In a double-blind study of 41 outpatients aged 55 to 80 years with mild memory impairment, the efficacy of dihydroergotoxine mesylate (DEM, Hydergine(R)) at 6 mg per day, administered orally, was tested during a twelve-week period. Specific etiologies for the amnesic syndrome were ruled out by history, physical examination, and laboratory tests. Subjects with a Hamilton Depression Scale rating above 18, ie, possible pseudodementia, were excluded. Physician rating of memory, employing the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), indicated statistically significant improvement of memory function in DEM treated subjects (N = 22) v those on placebo (N = 19), (F = 3.34; df = 1,39; P < .04). In contrast, structured testing of recent memory using digit symbol substitution and Zahlenverbindungs test (ZVT) showed improvement in both groups (P < .001) with no significant intergroup differences (P < .10). Out results indicate that in cases of mild, though subjectively distressing impairment, DEM at higher dosages may help to enhance short-term memory function.

Original languageEnglish (US)
Pages (from-to)219-223
Number of pages5
JournalJournal of the American Geriatrics Society
Volume35
Issue number3
StatePublished - 1987
Externally publishedYes

Fingerprint

Ergoloid Mesylates
Double-Blind Method
Dementia
Factitious Disorders
Short-Term Memory
Physical Examination
Outpatients
History
Placebos
Depression
Physicians
Equipment and Supplies

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine(R)) in mild dementia. / Thienhaus, Ole J; Wheeler, B. G.; Simon, S.; Zemlan, F. P.; Hartford, J. T.

In: Journal of the American Geriatrics Society, Vol. 35, No. 3, 1987, p. 219-223.

Research output: Contribution to journalArticle

Thienhaus, Ole J ; Wheeler, B. G. ; Simon, S. ; Zemlan, F. P. ; Hartford, J. T. / A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine(R)) in mild dementia. In: Journal of the American Geriatrics Society. 1987 ; Vol. 35, No. 3. pp. 219-223.
@article{139924cf702f4f4288a078b897b096e0,
title = "A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine(R)) in mild dementia",
abstract = "In a double-blind study of 41 outpatients aged 55 to 80 years with mild memory impairment, the efficacy of dihydroergotoxine mesylate (DEM, Hydergine(R)) at 6 mg per day, administered orally, was tested during a twelve-week period. Specific etiologies for the amnesic syndrome were ruled out by history, physical examination, and laboratory tests. Subjects with a Hamilton Depression Scale rating above 18, ie, possible pseudodementia, were excluded. Physician rating of memory, employing the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), indicated statistically significant improvement of memory function in DEM treated subjects (N = 22) v those on placebo (N = 19), (F = 3.34; df = 1,39; P < .04). In contrast, structured testing of recent memory using digit symbol substitution and Zahlenverbindungs test (ZVT) showed improvement in both groups (P < .001) with no significant intergroup differences (P < .10). Out results indicate that in cases of mild, though subjectively distressing impairment, DEM at higher dosages may help to enhance short-term memory function.",
author = "Thienhaus, {Ole J} and Wheeler, {B. G.} and S. Simon and Zemlan, {F. P.} and Hartford, {J. T.}",
year = "1987",
language = "English (US)",
volume = "35",
pages = "219--223",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine(R)) in mild dementia

AU - Thienhaus, Ole J

AU - Wheeler, B. G.

AU - Simon, S.

AU - Zemlan, F. P.

AU - Hartford, J. T.

PY - 1987

Y1 - 1987

N2 - In a double-blind study of 41 outpatients aged 55 to 80 years with mild memory impairment, the efficacy of dihydroergotoxine mesylate (DEM, Hydergine(R)) at 6 mg per day, administered orally, was tested during a twelve-week period. Specific etiologies for the amnesic syndrome were ruled out by history, physical examination, and laboratory tests. Subjects with a Hamilton Depression Scale rating above 18, ie, possible pseudodementia, were excluded. Physician rating of memory, employing the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), indicated statistically significant improvement of memory function in DEM treated subjects (N = 22) v those on placebo (N = 19), (F = 3.34; df = 1,39; P < .04). In contrast, structured testing of recent memory using digit symbol substitution and Zahlenverbindungs test (ZVT) showed improvement in both groups (P < .001) with no significant intergroup differences (P < .10). Out results indicate that in cases of mild, though subjectively distressing impairment, DEM at higher dosages may help to enhance short-term memory function.

AB - In a double-blind study of 41 outpatients aged 55 to 80 years with mild memory impairment, the efficacy of dihydroergotoxine mesylate (DEM, Hydergine(R)) at 6 mg per day, administered orally, was tested during a twelve-week period. Specific etiologies for the amnesic syndrome were ruled out by history, physical examination, and laboratory tests. Subjects with a Hamilton Depression Scale rating above 18, ie, possible pseudodementia, were excluded. Physician rating of memory, employing the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), indicated statistically significant improvement of memory function in DEM treated subjects (N = 22) v those on placebo (N = 19), (F = 3.34; df = 1,39; P < .04). In contrast, structured testing of recent memory using digit symbol substitution and Zahlenverbindungs test (ZVT) showed improvement in both groups (P < .001) with no significant intergroup differences (P < .10). Out results indicate that in cases of mild, though subjectively distressing impairment, DEM at higher dosages may help to enhance short-term memory function.

UR - http://www.scopus.com/inward/record.url?scp=0023137566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023137566&partnerID=8YFLogxK

M3 - Article

C2 - 3819261

AN - SCOPUS:0023137566

VL - 35

SP - 219

EP - 223

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 3

ER -